Latest Nanostring Technologies Inc (NSTG) Headlines
NanoString Technologies Releases Fourth Quarter and Full Year 2013 Financial Results and Provides 2014 Outlook
GlobeNewswire - Wed Feb 26, 3:09PM CST
- Strong Q4 2013 Revenue Growth of 56% Year over Year -
NanoString Technologies to Participate in the Cowen 34th Annual Health Care Conference
GlobeNewswire - Wed Feb 19, 3:05PM CST
NanoString Technologies, Inc. (Nasdaq:NSTG), today announced that its management is scheduled to participate in the Cowen 34 Annual Health Care Conference in Boston.
Study Confirms Ability of the Prosigna Assay to Assess Risk of Late Distant Recurrence in Postmenopausal Women With Estrogen Receptor-Positive Breast Cancer
Business Wire - Wed Feb 12, 6:30AM CST
NanoString Technologies, Inc., (NASDAQ:NSTG) a provider of life science tools for translational research and molecular diagnostic products, today announced that a study published online in Clinical Cancer Research showed that the PAM50 assay, on which the company's Prosigna(TM) Breast Cancer Prognostic Gene Signature Assay is based, accurately assessed the risk of late distant recurrence in postmenopausal women with estrogen receptor-positive (ER+) early-stage breast cancer. The study, titled, "The PAM50 Risk-of-Recurrence Score Predicts Risk for Late Distant Recurrence after Endocrine Therapy in Postmenopausal Women with Endocrine-Responsive Early Breast Cancer" was conducted by researchers from the Austrian Breast & Colorectal Cancer Study Group and can be found online at: http://clincancerres.aacrjournals.org/content...5.abstract.
NanoString Technologies Launches Commercial Reagents to Enable Laboratories to Rapidly Develop Tests From Translational Research Discoveries
Business Wire - Tue Feb 11, 6:30AM CST
NanoString Technologies, Inc. (NASDAQ: NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced the global commercial launch of the nCounter Elements(TM) General Purpose Reagents (GPRs), a solution that enables clinical laboratories to independently develop multiplexed genomic assays and then rapidly translate those assays into clinical diagnostics as Laboratory Developed Tests (LDTs). The announcement, made at the 21st International Molecular Medicine Tri-Conference (TRI-CON) taking place in San Francisco, February 9 - 14, marks the conclusion of a successful early access program that involved 22 participants from five countries in North America, Europe, and Asia.
NanoString Technologies to Release Fourth Quarter 2013 Financial Results and Host Conference Call on Wednesday, February 26, 2014
GlobeNewswire - Wed Feb 05, 3:05PM CST
NanoString Technologies, Inc. (Nasdaq:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the company will release 2013 fourth quarter financial results after the close of trading on Wednesday, February 26, 2014. Company management will host an investment community conference call beginning at 4:30pm ET to discuss those results and to provide a business update.
NanoString Technologies to Participate in the Leerink Swann Global Healthcare Conference 2014
GlobeNewswire - Wed Jan 29, 3:02PM CST
NanoString Technologies, Inc. (Nasdaq:NSTG), today announced that its management is scheduled to participate in the Leerink Swann Global Healthcare Conference 2014 in New York.
NanoString Technologies Inc prices USD55m in follow-on offering
M2 - Fri Jan 24, 4:18AM CST
Molecular diagnostic company NanoString Technologies Inc reported on Thursday that it has priced a follow-on public offering of USD55m of its common stock.
NanoString Technologies Prices Follow-On Offering
GlobeNewswire - Thu Jan 23, 5:30PM CST
NanoString Technologies, Inc., a provider of life science tools for translational research and molecular diagnostic products, today announced the pricing of its follow-on public offering of $55 million of its common stock at a price to the public of $18.50 per share. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional $8.25 million of its common stock.
NanoString Technologies Inc announces USD55m in follow-on public offering
M2 - Wed Jan 22, 3:57AM CST
Molecular diagnostic company NanoString Technologies Inc (NasdaqGM:NSTG) reported on Tuesday USD55m proposed follow-on public offering of its common stock.
NanoString Technologies Launches Follow-On Offering
GlobeNewswire - Tue Jan 21, 3:01PM CST
NanoString Technologies, Inc., a provider of life science tools for translational research and molecular diagnostic products, today announced the launch of a proposed follow-on public offering of $55 million of its common stock. In addition, the Company expects to grant the underwriters a 30-day option to purchase up to an additional $8.25 million of its common stock.
LabCorp Launches Breast Cancer Assay - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 15, 4:37PM CST
Laboratory Corp. announced the commercial launch of Prosigna Breast Cancer Prognostic Gene Signature Assay.
NanoString Technologies Secures Exclusive Option From Massachusetts General Hospital to License Intellectual Property for New Multiplexed Protein Analysis Method
GlobeNewswire - Wed Jan 15, 3:05PM CST
NanoString Technologies, Inc. (Nasdaq:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that it has secured an exclusive option from Massachusetts General Hospital to license intellectual property related to a novel approach for multiplexed protein analysis using the company's nCounter Analysis System. The method was recently published in Science Translational Medicine.
NanoString Technologies Inc files registration statement for USD55m in follow-on public offering
M2 - Tue Jan 14, 5:58AM CST
Life science company NanoString Technologies Inc (NasdaqGM) said on Monday that it has filed a registration statement for a planned follow-on offering of USD55m of its common stock to the public.
LabCorp to Offer New FDA approved Breast Cancer Prognostic Test
Business Wire - Mon Jan 13, 7:44AM CST
Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH) announced today the launch of the Prosigna(TM) Breast Cancer Prognostic Gene Signature Assay, an FDA approved breast cancer prognostic gene signature assay developed by NanoString Technologies, Inc. Prosigna provides a risk category and a numerical score to assess the probability of breast cancer recurrence in certain female breast cancer patients.
NanoString Technologies Files Registration Statement With SEC for a Follow-On Public Offering
GlobeNewswire - Mon Jan 13, 7:35AM CST
NanoString Technologies, Inc., a provider of life science tools for translational research and molecular diagnostic products, today announced that it has filed a registration statement with the U.S. Securities and Exchange Commission for a proposed follow-on public offering of $55 million of its common stock. In addition, the Company expects to grant the underwriters a 30-day option to purchase up to an additional $8.25 million of its common stock.
NanoString Technologies Announces Preliminary Unaudited Fourth Quarter 2013 Revenue
GlobeNewswire - Mon Jan 13, 6:30AM CST
Approximately 55% fourth quarter and 37% full year 2013 year-over-year revenue growth anticipated
NanoString Technologies to Present at the JP Morgan 32nd Annual Healthcare Conference
GlobeNewswire - Mon Jan 06, 3:05PM CST
NanoString Technologies, Inc. (Nasdaq:NSTG) today announced that its management is scheduled to participate in the JP Morgan 32 Annual Healthcare Conference on January 15, 2014 in San Francisco.
Stryker Buys Patient Safety - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 03, 3:40PM CST
SYK decided to buy Irvine, Calif.-based Patient Safety Technologies in order to utilize Patient Safety's device to lessen the risk of surgical sponges being left in patients after surgery
NanoString Technologies Announces Publication of Pivotal ABCSG-8 Study of the Prosigna Breast Cancer Assay
Business Wire - Wed Dec 18, 4:22PM CST
NanoString Technologies, Inc., (NASDAQ: NSTG) a provider of life science tools for translational research and molecular diagnostic products, today announced that Annals of Oncology, the journal of the European Society of Medical Oncology, has published a pivotal study validating the Prosigna(TM) Breast Cancer Prognostic Gene Signature Assay for predicting the risk of distant recurrence in postmenopausal women with Hormone Receptor-Positive (HR+) early-stage breast cancer. The study was based on an analysis of the Austrian Breast & Colorectal Cancer Study Group 8 (ABCSG-8) trial and concluded that patients categorized by the Prosigna Assay as low risk are unlikely to benefit from additional chemotherapy. As a result of the authors independently replicating the results of the recently published TransATAC study, this study also showed that the Prosigna Assay has achieved Level 1 Evidence, the standard typically required for inclusion in cancer treatment guidelines.
PAM50-Based Prosigna Breast Cancer Assay Helps to Identify Patients at Risk of Late Distant Recurrence in a Combined Analysis of 2,137 Patients
Business Wire - Fri Dec 13, 4:30PM CST
NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced new results from a combined analysis of the Austrian Breast & Colorectal Cancer Study Group 8 (ABCSG-8) and Trans-Arimidex, Tamoxifen, Alone or in Combination (TransATAC) studies. These results, which evaluated samples from 2,137 patients, suggest that the PAM50-based Prosigna(TM) Breast Cancer Prognostic Gene Signature Assay may help identify women with late distant recurrence after five years of endocrine treatment. Using the Prosigna Assay, the study investigators classified patient tumors by subtype and found that patients with Luminal B subtype have three times higher risk of late distant recurrence than patients with Luminal A subtype tumors(1). Results were presented today at the 2013 San Antonio Breast Cancer Symposium.
NanoString Technologies Releases Fourth Quarter and Full Year 2013 Financial Results and Provides 2014 Outlook
GlobeNewswire - Wed Feb 26, 3:09PM CST
- Strong Q4 2013 Revenue Growth of 56% Year over Year -
NanoString Technologies to Participate in the Cowen 34th Annual Health Care Conference
GlobeNewswire - Wed Feb 19, 3:05PM CST
NanoString Technologies, Inc. (Nasdaq:NSTG), today announced that its management is scheduled to participate in the Cowen 34 Annual Health Care Conference in Boston.
Study Confirms Ability of the Prosigna Assay to Assess Risk of Late Distant Recurrence in Postmenopausal Women With Estrogen Receptor-Positive Breast Cancer
Business Wire - Wed Feb 12, 6:30AM CST
NanoString Technologies, Inc., (NASDAQ:NSTG) a provider of life science tools for translational research and molecular diagnostic products, today announced that a study published online in Clinical Cancer Research showed that the PAM50 assay, on which the company's Prosigna(TM) Breast Cancer Prognostic Gene Signature Assay is based, accurately assessed the risk of late distant recurrence in postmenopausal women with estrogen receptor-positive (ER+) early-stage breast cancer. The study, titled, "The PAM50 Risk-of-Recurrence Score Predicts Risk for Late Distant Recurrence after Endocrine Therapy in Postmenopausal Women with Endocrine-Responsive Early Breast Cancer" was conducted by researchers from the Austrian Breast & Colorectal Cancer Study Group and can be found online at: http://clincancerres.aacrjournals.org/content...5.abstract.
NanoString Technologies Launches Commercial Reagents to Enable Laboratories to Rapidly Develop Tests From Translational Research Discoveries
Business Wire - Tue Feb 11, 6:30AM CST
NanoString Technologies, Inc. (NASDAQ: NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced the global commercial launch of the nCounter Elements(TM) General Purpose Reagents (GPRs), a solution that enables clinical laboratories to independently develop multiplexed genomic assays and then rapidly translate those assays into clinical diagnostics as Laboratory Developed Tests (LDTs). The announcement, made at the 21st International Molecular Medicine Tri-Conference (TRI-CON) taking place in San Francisco, February 9 - 14, marks the conclusion of a successful early access program that involved 22 participants from five countries in North America, Europe, and Asia.
NanoString Technologies to Release Fourth Quarter 2013 Financial Results and Host Conference Call on Wednesday, February 26, 2014
GlobeNewswire - Wed Feb 05, 3:05PM CST
NanoString Technologies, Inc. (Nasdaq:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the company will release 2013 fourth quarter financial results after the close of trading on Wednesday, February 26, 2014. Company management will host an investment community conference call beginning at 4:30pm ET to discuss those results and to provide a business update.
NanoString Technologies to Participate in the Leerink Swann Global Healthcare Conference 2014
GlobeNewswire - Wed Jan 29, 3:02PM CST
NanoString Technologies, Inc. (Nasdaq:NSTG), today announced that its management is scheduled to participate in the Leerink Swann Global Healthcare Conference 2014 in New York.
NanoString Technologies Inc prices USD55m in follow-on offering
M2 - Fri Jan 24, 4:18AM CST
Molecular diagnostic company NanoString Technologies Inc reported on Thursday that it has priced a follow-on public offering of USD55m of its common stock.
NanoString Technologies Prices Follow-On Offering
GlobeNewswire - Thu Jan 23, 5:30PM CST
NanoString Technologies, Inc., a provider of life science tools for translational research and molecular diagnostic products, today announced the pricing of its follow-on public offering of $55 million of its common stock at a price to the public of $18.50 per share. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional $8.25 million of its common stock.
NanoString Technologies Inc announces USD55m in follow-on public offering
M2 - Wed Jan 22, 3:57AM CST
Molecular diagnostic company NanoString Technologies Inc (NasdaqGM:NSTG) reported on Tuesday USD55m proposed follow-on public offering of its common stock.
NanoString Technologies Launches Follow-On Offering
GlobeNewswire - Tue Jan 21, 3:01PM CST
NanoString Technologies, Inc., a provider of life science tools for translational research and molecular diagnostic products, today announced the launch of a proposed follow-on public offering of $55 million of its common stock. In addition, the Company expects to grant the underwriters a 30-day option to purchase up to an additional $8.25 million of its common stock.
LabCorp Launches Breast Cancer Assay - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 15, 4:37PM CST
Laboratory Corp. announced the commercial launch of Prosigna Breast Cancer Prognostic Gene Signature Assay.
NanoString Technologies Secures Exclusive Option From Massachusetts General Hospital to License Intellectual Property for New Multiplexed Protein Analysis Method
GlobeNewswire - Wed Jan 15, 3:05PM CST
NanoString Technologies, Inc. (Nasdaq:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that it has secured an exclusive option from Massachusetts General Hospital to license intellectual property related to a novel approach for multiplexed protein analysis using the company's nCounter Analysis System. The method was recently published in Science Translational Medicine.
NanoString Technologies Inc files registration statement for USD55m in follow-on public offering
M2 - Tue Jan 14, 5:58AM CST
Life science company NanoString Technologies Inc (NasdaqGM) said on Monday that it has filed a registration statement for a planned follow-on offering of USD55m of its common stock to the public.
LabCorp to Offer New FDA approved Breast Cancer Prognostic Test
Business Wire - Mon Jan 13, 7:44AM CST
Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH) announced today the launch of the Prosigna(TM) Breast Cancer Prognostic Gene Signature Assay, an FDA approved breast cancer prognostic gene signature assay developed by NanoString Technologies, Inc. Prosigna provides a risk category and a numerical score to assess the probability of breast cancer recurrence in certain female breast cancer patients.
NanoString Technologies Files Registration Statement With SEC for a Follow-On Public Offering
GlobeNewswire - Mon Jan 13, 7:35AM CST
NanoString Technologies, Inc., a provider of life science tools for translational research and molecular diagnostic products, today announced that it has filed a registration statement with the U.S. Securities and Exchange Commission for a proposed follow-on public offering of $55 million of its common stock. In addition, the Company expects to grant the underwriters a 30-day option to purchase up to an additional $8.25 million of its common stock.
NanoString Technologies Announces Preliminary Unaudited Fourth Quarter 2013 Revenue
GlobeNewswire - Mon Jan 13, 6:30AM CST
Approximately 55% fourth quarter and 37% full year 2013 year-over-year revenue growth anticipated
NanoString Technologies to Present at the JP Morgan 32nd Annual Healthcare Conference
GlobeNewswire - Mon Jan 06, 3:05PM CST
NanoString Technologies, Inc. (Nasdaq:NSTG) today announced that its management is scheduled to participate in the JP Morgan 32 Annual Healthcare Conference on January 15, 2014 in San Francisco.
Stryker Buys Patient Safety - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 03, 3:40PM CST
SYK decided to buy Irvine, Calif.-based Patient Safety Technologies in order to utilize Patient Safety's device to lessen the risk of surgical sponges being left in patients after surgery
NanoString Technologies Announces Publication of Pivotal ABCSG-8 Study of the Prosigna Breast Cancer Assay
Business Wire - Wed Dec 18, 4:22PM CST
NanoString Technologies, Inc., (NASDAQ: NSTG) a provider of life science tools for translational research and molecular diagnostic products, today announced that Annals of Oncology, the journal of the European Society of Medical Oncology, has published a pivotal study validating the Prosigna(TM) Breast Cancer Prognostic Gene Signature Assay for predicting the risk of distant recurrence in postmenopausal women with Hormone Receptor-Positive (HR+) early-stage breast cancer. The study was based on an analysis of the Austrian Breast & Colorectal Cancer Study Group 8 (ABCSG-8) trial and concluded that patients categorized by the Prosigna Assay as low risk are unlikely to benefit from additional chemotherapy. As a result of the authors independently replicating the results of the recently published TransATAC study, this study also showed that the Prosigna Assay has achieved Level 1 Evidence, the standard typically required for inclusion in cancer treatment guidelines.
PAM50-Based Prosigna Breast Cancer Assay Helps to Identify Patients at Risk of Late Distant Recurrence in a Combined Analysis of 2,137 Patients
Business Wire - Fri Dec 13, 4:30PM CST
NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced new results from a combined analysis of the Austrian Breast & Colorectal Cancer Study Group 8 (ABCSG-8) and Trans-Arimidex, Tamoxifen, Alone or in Combination (TransATAC) studies. These results, which evaluated samples from 2,137 patients, suggest that the PAM50-based Prosigna(TM) Breast Cancer Prognostic Gene Signature Assay may help identify women with late distant recurrence after five years of endocrine treatment. Using the Prosigna Assay, the study investigators classified patient tumors by subtype and found that patients with Luminal B subtype have three times higher risk of late distant recurrence than patients with Luminal A subtype tumors(1). Results were presented today at the 2013 San Antonio Breast Cancer Symposium.
